24 March 2016: Epiduo letter
Published 26 April 2016
© Crown copyright 2016
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-march-2016/24-march-2016-epiduo-letter
MHRA received an anonymous complaint concerning a letter sent out by Galderma in April 2015 about the use of Epiduo (adapalene/benzoyl peroxide) in pregnancy. The complainant alleged that the letter was misleading as to the appropriate use of the product in women of child bearing age.
MHRA did not uphold the complaint because the letter was consistent with the SPC and quoted the relevant section in full. Epiduo should not be used in pregnancy but SPCs for adapalene products were amended in 2009 to remove restrictions on use in women of child bearing age.